The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: NeoRad Breast Cancer Study
Official Title: Neoadjuvant Chemotherapy Followed by Preoperative Radiotherapy in High-risk Breast Cancer: a Prospective, International Randomised Multicentre-phase III Trial
Study ID: NCT04261244
Brief Summary: The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NACT.
Detailed Description: The standard of care for high-risk breast cancer consists of neoadjuvant chemotherapy and surgery followed by postoperative whole breast/chest wall irradiation+/- an additional boost (= irradiation restricted to the tumour bed in the case of breast-conserving therapy). In case of lymph node involvement in most patients require additional radiation of the regional lymph nodes. Adjuvant radiotherapy significantly reduces ipsilateral breast cancer recurrences, breast cancer specific mortality, and overall mortality. The optimal time of radiotherapy in patients, who are candidates for neoadjuvant chemotherapy (NACT) has never been addressed in a randomised controlled trial.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Heinrich Heine University Hospital Duesseldorf, Duesseldorf, , Germany
Name: Christiane Matuschek, MD
Affiliation: University Hosptial Duesseldorf, Department of Radiotherapy and Radiooncology
Role: PRINCIPAL_INVESTIGATOR